Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial
Latest Information Update: 08 Nov 2022
At a glance
- Drugs Capecitabine (Primary) ; Tucidinostat (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 01 Nov 2022 Status changed from not yet recruiting to recruiting.
- 27 May 2022 New trial record